BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Shou Z, Fan H, Xu M, Chen Q, Tang Q, Liu X, Wu H, Zhang M, Yu T, Deng S, Liu Y. Protective effects of oxymatrine against DSS-induced acute intestinal inflammation in mice via blocking the RhoA/ROCK signaling pathway. Biosci Rep 2019;39:BSR20182297. [PMID: 31262973 DOI: 10.1042/BSR20182297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes DJAR, Oellerich M, Picard N, Salzmann L, Tönshoff B, van Schaik RHN, Vethe NT, Vinks AA, Wallemacq P, Åsberg A, Langman LJ. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 2021;43:150-200. [PMID: 33711005 DOI: 10.1097/FTD.0000000000000871] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kitani T, Maddipatla SC, Madupuri R, Greco C, Hartmann J, Baraniuk JN, Vasudevan S. In Search of Newer Targets for Inflammatory Bowel Disease: A Systems and a Network Medicine Approach. Network and Systems Medicine 2021;4:74-87. [DOI: 10.1089/nsm.2020.0012] [Reference Citation Analysis]
4 Silva NV, Carregosa D, Gonçalves C, Vieira OV, Nunes Dos Santos C, Jacinto A, Crespo CL. A Dietary Cholesterol-Based Intestinal Inflammation Assay for Improving Drug-Discovery on Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:674749. [PMID: 34150769 DOI: 10.3389/fcell.2021.674749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang JJ, Fan YH. Advances in research of tacrolimus for treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(13): 842-850 [DOI: 10.11569/wcjd.v27.i13.842] [Reference Citation Analysis]
6 Qv L, Mao S, Li Y, Zhang J, Li L. Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease. Front Cell Infect Microbiol 2021;11:755650. [PMID: 34900751 DOI: 10.3389/fcimb.2021.755650] [Reference Citation Analysis]
7 Ali FEM, M Elfiky M, Fadda WA, Ali HS, Mahmoud AR, Mohammedsaleh ZM, Abd-Elhamid TH. Regulation of IL-6/STAT-3/Wnt axis by nifuroxazide dampens colon ulcer in acetic acid-induced ulcerative colitis model: Novel mechanistic insight. Life Sci 2021;276:119433. [PMID: 33794250 DOI: 10.1016/j.lfs.2021.119433] [Reference Citation Analysis]
8 Kroesen AJ. Early Surgery in Inflammatory Bowel Diseases Is a Better Option than Prolonged Conservative Treatment. Visc Med 2019;35:355-8. [PMID: 31934583 DOI: 10.1159/000504150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Zhou Y, Zhong B, Min X, Hou Y, Lin L, Wu Q, Shi J, Chen X. Therapeutic potential of isobavachalcone, a natural flavonoid, in murine experimental colitis by inhibiting NF-κB p65. Phytother Res 2021;35:5861-70. [PMID: 34435401 DOI: 10.1002/ptr.7246] [Reference Citation Analysis]
10 Abaach M, Morilla I. Learning models for colorectal cancer signature reconstruction and classification in patients with chronic inflammatory bowel disease. Artif Intell Cancer 2022; 3(2): 27-41 [DOI: 10.35713/aic.v3.i2.27] [Reference Citation Analysis]
11 Liu S, Shen H, Li J, Gong Y, Bao H, Zhang J, Hu L, Wang Z, Gong J. Loganin inhibits macrophage M1 polarization and modulates sirt1/NF-κB signaling pathway to attenuate ulcerative colitis. Bioengineered 2020;11:628-39. [PMID: 33034242 DOI: 10.1080/21655979.2020.1774992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020;10:12546. [PMID: 32719413 DOI: 10.1038/s41598-020-68828-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Li H, Pang B, Nie B, Qu S, Zhang K, Xu J, Yang M, Liu J, Li S. Dioscin promotes autophagy by regulating the AMPK-mTOR pathway in ulcerative colitis. Immunopharmacol Immunotoxicol 2022;:1-9. [PMID: 35174751 DOI: 10.1080/08923973.2022.2037632] [Reference Citation Analysis]
15 García-Vicuña R, Garrido N, Gómez S, Joven B, Queiro R, Ramírez J, Rebollo F, Loza E, Sellas A. Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process. Rheumatol Int 2021;41:1549-65. [PMID: 33934175 DOI: 10.1007/s00296-021-04877-5] [Reference Citation Analysis]
16 Zergham AS, Sekhon AK, Mebasher A, Tserenpil G, Malik BH. Inflammatory Bowel Disease and Obstructive Pulmonary Disease: A Two-way Association? Cureus 2020;12:e6836. [PMID: 32181078 DOI: 10.7759/cureus.6836] [Reference Citation Analysis]
17 Kotla NG, Singh R, Baby BV, Rasala S, Rasool J, Hynes SO, Martin D, Egan LJ, Vemula PK, Jala VR, Rochev Y, Pandit A. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. Biomaterials 2022;281:121364. [DOI: 10.1016/j.biomaterials.2022.121364] [Reference Citation Analysis]
18 Li Y, Raza F, Liu Y, Wei Y, Rong R, Zheng M, Yuan W, Su J, Qiu M, Li Y, Raza F, Liu Y, Wei Y, Rong R, Zheng M, Yuan W, Su J, Qiu M. Clinical progress and advanced research of red blood cells based drug delivery system. Biomaterials 2021;279:121202. [PMID: 34749072 DOI: 10.1016/j.biomaterials.2021.121202] [Reference Citation Analysis]
19 Zhu T, Xue Q, Liu Y, Xu Y, Xiong C, Lu J, Yang H, Zhang Q, Huang Y. Analysis of Intestinal Microflora and Metabolites From Mice With DSS-Induced IBD Treated With Schistosoma Soluble Egg Antigen. Front Cell Dev Biol 2021;9:777218. [PMID: 34858992 DOI: 10.3389/fcell.2021.777218] [Reference Citation Analysis]
20 Zhou H, Ikeuchi-Takahashi Y, Hattori Y, Onishi H. Nanogels of a Succinylated Glycol Chitosan-Succinyl Prednisolone Conjugate: Release Behavior, Gastrointestinal Distribution, and Systemic Absorption. Int J Mol Sci 2020;21:E2376. [PMID: 32235554 DOI: 10.3390/ijms21072376] [Reference Citation Analysis]
21 Lin G, Li M, Xu N, Wu X, Liu J, Wu Y, Zhang Q, Cai J, Gao C, Su Z. Anti-Inflammatory Effects of Heritiera littoralis Fruits on Dextran Sulfate Sodium- (DSS-) Induced Ulcerative Colitis in Mice by Regulating Gut Microbiota and Suppressing NF-κB Pathway. Biomed Res Int 2020;2020:8893621. [PMID: 33354574 DOI: 10.1155/2020/8893621] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Yu J, Chen H, Xu J, Zhou P. Research advances in the role and pharmaceuticals of ATP-binding cassette transporters in autoimmune diseases. Mol Cell Biochem 2022. [PMID: 35034257 DOI: 10.1007/s11010-022-04354-y] [Reference Citation Analysis]
23 Song HY, Sik Kim W, Kim JM, Bak DH, Moo Han J, Lim ST, Byun EB. A hydroxyethyl derivative of chrysin exhibits anti-inflammatory activity in dendritic cells and protective effects against dextran sodium salt-induced colitis in mice. Int Immunopharmacol 2019;77:105958. [PMID: 31639615 DOI: 10.1016/j.intimp.2019.105958] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Cai J, Liu J, Fan P, Dong X, Zhu K, Liu X, Zhang N, Cao Y. Dioscin prevents DSS-induced colitis in mice with enhancing intestinal barrier function and reducing colon inflammation. Int Immunopharmacol 2021;99:108015. [PMID: 34339962 DOI: 10.1016/j.intimp.2021.108015] [Reference Citation Analysis]
25 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Reference Citation Analysis]
26 Wang Y, Duan X, Liu X, Liu Y, Fan H, Xu M, Chen Q, Tang Q. Rho kinase Blockade Ameliorates DSS-Induced Ulcerative Colitis in Mice Through Dual Inhibition of the NF-κB and IL-6/STAT3 Pathways. Inflammation 2020;43:857-67. [PMID: 31916050 DOI: 10.1007/s10753-019-01171-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
29 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
30 Harmand PO, Solassol J. Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes (Basel) 2020;11:E1212. [PMID: 33081236 DOI: 10.3390/genes11101212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kimura Y. Effects of kampo medicine keishikashakuyakuto on large intestine disease in mice. Traditional & Kampo Medicine 2019;6:165-72. [DOI: 10.1002/tkm2.1232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Bokemeyer B, Ghiani M, Fuchs A, Deiters B, Hardtstock F, Brandes A, Knop J, Orzechowski HD, Wilke T. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. Int J Colorectal Dis 2020;35:1587-98. [PMID: 32424526 DOI: 10.1007/s00384-020-03588-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Weitman M, Bejar C, Melamed M, Weill T, Yanovsky I, Zeeli S, Nudelman A, Weinstock M. Comparison of the tissue distribution and metabolism of AN1284, a potent anti-inflammatory agent, after subcutaneous and oral administration in mice. Naunyn Schmiedebergs Arch Pharmacol 2021. [PMID: 34309687 DOI: 10.1007/s00210-021-02125-y] [Reference Citation Analysis]